Athanasios Tampakis1,2, Ekaterini Christina Tampaki3, Afroditi Nonni4, Raoul Droeser5, Alberto Posabella5, Gerasimos Tsourouflis3, Konstantinos Kontzoglou3, Efstratios Patsouris4, Markus von Flüe5, Gregory Kouraklis3. 1. Clarunis University Center of Gastrointestinal and Liver Disorders, Department of Visceral Surgery, University Hospital Basel, Basel, Switzerland, Athantamp@hotmail.com. 2. 2nd Department of Propedeutic Surgery, Athens University Medical School, Laiko General Hospital, Athens, Greece, Athantamp@hotmail.com. 3. 2nd Department of Propedeutic Surgery, Athens University Medical School, Laiko General Hospital, Athens, Greece. 4. 1st Department of Pathology, School of Medicine, National University of Athens, Athens, Greece. 5. Clarunis University Center of Gastrointestinal and Liver Disorders, Department of Visceral Surgery, University Hospital Basel, Basel, Switzerland.
Abstract
BACKGROUND: Despite improvements in therapy of colorectal cancer, some patients will present occurrence of recurrence either locally or distantly. Tumor metastasis constitutes the major cause of cancer-associated morbidity and mortality. Nectin-1 belongs to the family of immunoglobulin-like cell adhesion molecules that contribute to the formation of cell-cell adhesions and regulate a series of cellular activities including cell polarization, differentiation, movement, proliferation, and survival. Expression of Nectin-1 in malignant tumors has been associated with aggressive tumor phenotypes. OBJECTIVES: The aim of the present study was to assess Nectin-1 expression patterns in colorectal cancer and to investigate its clinical significance. METHODS: Nectin-1 expression was assessed via immunohistochemistry in surgical specimens of a cohort comprised of 111 patients with primary resectable colorectal cancer. Results were correlated with clinicopathological characteristics and survival data. Progression-free survival was defined as the primary outcome of the present study. RESULTS: Nectin-1 was strongly expressed in the cytoplasm of colorectal cancer cells. High Nectin-1 expression was associated with advanced stage of disease (p = 0.012) and lymph node metastasis (p = 0.007). Progression-free survival of patients exhibiting high expression of Nectin-1 in the first 36 months after surgery was significantly worse compared to patients with low expression of Nectin-1 (55.7%, 95% CI = 47-70, vs. 82.1%, 95% CI = 69-93, p = 0.014) and independent of other clinicopathological characteristics (HR = 0.389, 95% CI = 0.156-0.972, p = 0.043). CONCLUSION: Nectin-1 expression in colorectal cancer is associated with a significantly worse 3-year progression-free survival identifying therefore a group of patients with high risk for early disease recurrence.
BACKGROUND: Despite improvements in therapy of colorectal cancer, some patients will present occurrence of recurrence either locally or distantly. Tumor metastasis constitutes the major cause of cancer-associated morbidity and mortality. Nectin-1 belongs to the family of immunoglobulin-like cell adhesion molecules that contribute to the formation of cell-cell adhesions and regulate a series of cellular activities including cell polarization, differentiation, movement, proliferation, and survival. Expression of Nectin-1 in malignant tumors has been associated with aggressive tumor phenotypes. OBJECTIVES: The aim of the present study was to assess Nectin-1 expression patterns in colorectal cancer and to investigate its clinical significance. METHODS:Nectin-1 expression was assessed via immunohistochemistry in surgical specimens of a cohort comprised of 111 patients with primary resectable colorectal cancer. Results were correlated with clinicopathological characteristics and survival data. Progression-free survival was defined as the primary outcome of the present study. RESULTS:Nectin-1 was strongly expressed in the cytoplasm of colorectal cancer cells. High Nectin-1 expression was associated with advanced stage of disease (p = 0.012) and lymph node metastasis (p = 0.007). Progression-free survival of patients exhibiting high expression of Nectin-1 in the first 36 months after surgery was significantly worse compared to patients with low expression of Nectin-1 (55.7%, 95% CI = 47-70, vs. 82.1%, 95% CI = 69-93, p = 0.014) and independent of other clinicopathological characteristics (HR = 0.389, 95% CI = 0.156-0.972, p = 0.043). CONCLUSION:Nectin-1 expression in colorectal cancer is associated with a significantly worse 3-year progression-free survival identifying therefore a group of patients with high risk for early disease recurrence.
Authors: Ae-Ri Ahn; Sang Jae Noh; Usama Khamis Hussein; Ho Sung Park; Myoung Ja Chung; Ho Lee; Woo Sung Moon; Myoung Jae Kang; Hyung Jin Kim; Na Ri Lee; Kyu Yun Jang; Kyoung Min Kim Journal: BMC Urol Date: 2021-10-08 Impact factor: 2.264